Suicide gene therapy, directed against proteins that comprise the senescence signature, appears more efficacious in clearing p16Ink4a-overexpressing tumor cells (with mutations in downstream effectors of p16Ink4a+ such as RB and CDK4/6) as well as normal senescent cells than direct attempts to eliminate these cells with senolytic drugs [82]. The gene discussed is RB1; the disease is neoplasm.